Mr Mrs Miss Ms Dr Other

Dr
Delphine
Lauté-Caly

Trainee Patent Attorney

Aberdeen Office Paris Office

Life sciences

Telephone. +44 (0)1224 258 510
Email. dlautecaly@hgf.com

Experience

Delphine joined HGF's Aberdeen office in August 2023 as a Trainee Patent Attorney within the Life Sciences team, where she supports the work of the Microbiome, Agritech and Plant Variety Rights teams.

She has a keen interest in microbiome research, with a particular focus on how beneficial microbes can be harnessed to develop innovative human therapeutics and biotechnological solutions for agriculture.

Delphine has a strong scientific background, with more than 15 years experience in both academic and industry settings. She holds a PhD in Microbiology from University College Cork, and a Master's degree in Agri-Food Sciences and a Master's degree in Bioprocesses and Plant Biotechnologies from Université de Lille in France.

During her post-doctoral positions in Ireland and France, she specialised in molecular microbiology, studying gene regulation and protein expression in human and plant bacterial pathogenic and probiotic strains.

Delphine has an extensive knowledge of the human microbiome and bacterial engineering. Prior to joining HGF, she worked for 7 years in a microbiome therapeutics company, where her work focused on the mechanism of action of live biotherapeutic products and the genetic manipulation of non-model microorganisms.

Qualifications

Trainee


MSC

MSc in Bioprocesses and Plant Biotechnologies

MSC

MSc in Agri-food Engineering

PHD

PhD in Microbiology

POSTGRADUATE DIPLOMA OR CERTIFICATE

Postgraduate Certificate in Intellectual Property Law

Related News

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

Unlocking the Soil Microbiome: Driving Agritech Innovation in the UK

The UK offers an ideal platform for harnessing the untapped potential of soil and plant microorganisms. Although much of my professional experience has focused on the human microbiome, I have …

Read article

The Antibody Series #2 | Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Read article

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Introduction Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.